US Pharma MarketingAt ASCO, drugmakers to offer options after Keytruda in head and neck cancer
Drugmakers are exploring a variety of approaches to treat head and neck cancers, from bispecific antibodies that target both PD-1 and VEGF to antibody-drug conjugates that deliver more targeted attacks. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the…
Head and neck cancer has always been a tough nut to crack. These tumors can suppress immune responses through multiple pathways, meaning blocking one of those usually isn’t enough.
Merck’s Keytruda is approved for head ...
Source: Endpoints News